Oral Anticoagulants Demonstrate Value in Management of Acute VTE

Katherine C. Rappazzo, MD, and Jennifer R. Green, MD
Published: Wednesday, Apr 10, 2019
vanderbilt-cancer-centerKatherine C. Rappazzo,
MD
Katherine C. Rappazzo, MD
Resident, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
 
Jennifer R. Green, MD
Jennifer R. Green, MD
 
Assistant Professor of Medicine,
Director of the Vanderbilt Hemophilia/ Hemostasis Treatment Clinic,
Vanderbilt University Medical Center, Nashville, Tennessee
Strategic Partnership
In the treatment of acute venous thromboembolism (VTE) associated with an underlying malignancy, direct oral anticoagulants (DOACs) are now considered acceptable for some patient populations. National Comprehensive Cancer Network Guidelines indicate that low molecular weight heparin (LMWH) is an appropriate anticoagulant for the first 6 months in patients with proximal deep vein thrombosis or pulmonary embolism.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
Publication Bottom Border
Border Publication
x